Cervical Papanicolaou tests in the female-to-male transgender population: should the adequacy criteria be revised in this population? An Institutional Experience
| Autor: | Sarah Kelting, Regina M. Plummer, Fang Fan, Rashna Madan, Katie Dennis, Maura O'Neil |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Population Uterine Cervical Neoplasms Papanicolaou stain 030209 endocrinology & metabolism Cervix Uteri Alphapapillomavirus Transgender Persons Pathology and Forensic Medicine Young Adult 03 medical and health sciences 0302 clinical medicine Humans Medicine education Cervix Early Detection of Cancer Aged Aged 80 and over Vaginal Smears Cervical cancer education.field_of_study business.industry Obstetrics Papillomavirus Infections Papanicolaou Test Middle Aged Uterine Cervical Dysplasia medicine.disease Squamous intraepithelial lesion medicine.anatomical_structure Androgen Therapy 030220 oncology & carcinogenesis Cohort Androgens Female Atrophy business Follow-Up Studies |
| Zdroj: | Journal of the American Society of Cytopathology. 10:255-260 |
| ISSN: | 2213-2945 |
| DOI: | 10.1016/j.jasc.2021.01.004 |
| Popis: | Introduction It is recommended that female-to-male (FTM) transgender patients with a cervix follow the same cervical cancer screening guidelines as cisgender women. This study analyzes Papanicolaou tests, HPV results, and follow-up histology in FTM patients, and compares those results to other atrophic populations at our institution. Materials and methods A cohort of FTM patients receiving androgen therapy was identified through our institution’s translational research database. We collected data on Papanicolaou tests, human papillomavirus (HPV) results, follow-up surgical procedures, and duration of androgen therapy. ThinPrep slides were reviewed for cellularity and cytomorphology. The results of these tests were compared with those of an atrophic control group consisting of postpartum and postmenopausal cisgender women. Results We identified 71 FTM patients with 77 Papanicolaou tests collected over 6 years. Papanicolaou interpretations included: negative for intraepithelial lesion (69%), atypical cells of undermined significance (5%), low grade squamous intraepithelial lesion (1%), atypical glandular cells (1%), and unsatisfactory due to inadequate cellularity (23%). Five of 27 (18.5%) HPV tests were positive. Follow-up surgical specimens did not identify high-grade lesions. Unsatisfactory rates among FTM patients differed significantly from the atrophic group (P 0.05). Most FTM Papanicolaou tests reviewed showed features of atrophy. Conclusions FTM patients receiving androgen have high Papanicolaou test unsatisfactory rates secondary to atrophy. Epithelial abnormality and HPV rates do not differ significantly from atrophic cisgender patients. Lowering the cellularity threshold for this population to 2000 like that of other atrophic groups should be considered. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect